Figure 3

Generation of tumor-targeting scFv(h-AM1)-BAP-RICIA immunoconjugates. (a) Titration of scFv(h-AM1)-BAP against avidin in increasing molar ratios for the estimation of adequate conjugation conditions. Western blot analysis was performed to detect complexes via the c-myc epitope and free biotinylated scFv(h-AM1)-BAP. (b) Schematic representation of the successive conjugation of tumor-targeting RICIA. (c) Size of assembled scFv(h-AM1)-BAP-RICIA immunoconjugates was investigated using in situ atomic force microscopy (AFM).